NA-Selank Amidate vs Humanin

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

NA-Selank Amidate

NA-Selank Amidate (N-Acetyl Selank Amidate) is an enhanced version of Selank with improved stability and blood-brain barrier penetration. The modifications increase bioavailability and duration of cognitive and anxiolytic effects.

Full details →

Humanin

Humanin is a mitochondrial-derived peptide with potent cytoprotective effects. Discovered in 2001, it has shown promise in protecting against age-related diseases including Alzheimer's, cardiovascular disease, and diabetes.

Full details →

Side-by-Side Comparison

AspectNA-Selank AmidateHumanin
MechanismSame core mechanism as Selank - modulates BDNF, serotonin, and norepinephrine systems. The N-acetyl group improves membrane permeability while the amidate modification increases enzymatic stability.Binds to IGFBP-3 and BAX, inhibiting apoptosis. Activates STAT3 signaling and enhances cellular survival under stress. Protects mitochondrial function and reduces oxidative stress.
Typical DosageIntranasal: 100-400mcg 1-3 times daily. Lower doses needed compared to standard Selank due to enhanced bioavailability.Research protocols vary widely. Studies have used doses from micrograms to milligrams depending on the analog and route. HNG (S14G-Humanin) is a more potent analog.
AdministrationPrimarily intranasal administration. Can be used sublingually. More stable in solution than standard Selank.Subcutaneous or intraperitoneal injection in research. Various analogs exist with different potencies and stabilities.
Side EffectsGenerally well-tolerated. Possible mild fatigue or nasal irritation. Less frequent dosing needed than standard Selank.Limited human data. Generally well-tolerated in animal studies. May affect glucose metabolism.
Best For

What They Have in Common

Both NA-Selank Amidate and Humanin are commonly used for:

Key Differences

Unique to NA-Selank Amidate:

Unique to Humanin:

Ready to Learn More?